Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone. 

Merck Global Health Innovation Fund

Casdin Capital

D1 Capital Partners

Fidelity

aMoon Fund

ArrowMark Partners

Fidelity Management and Research Company

Perceptive Advisors

Redmile Group

Helicase Venture

Irving Investors

Absci

We’re excited to announce our new strategic partnership with PrecisionLife. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. By combining our unique strengths, our goal is to create better therapies for patients with diseases that have long been challenging to treat.

Read more here: https://lnkd.in/gr3Qsp8b

#AI #Biologics #DrugDiscovery #PrecisionMedicine

For our annual Unlimiter Day this past Friday, employees from around the world gathered at our HQ in Vancouver, WA to celebrate our achievements in 2023 and plan for continued success in 2024 as we work with our new collaborators like AstraZeneca, Almirall, and PrecisionLife and continue developing our pipeline of new programs like our TL1A antibody ABS-101.

Then on Saturday, we put one of our core values, “We embrace our differences”, into action as Unlimiters volunteered with STEM Like a Girl to help build STEM kits that will be used in local schools to inspire participation in the sciences.

#AI #DrugDiscovery

Please enjoy my interview with Absci CEO Sean McClain

“We're on track to put the first de novo designed antibody with generative AI in the clinic in early 2025.”

Absci, a biotech startup using “generative AI” to create novel therapeutics, is hopefully just one year away from going into the clinic with its first design. That has already pushed Big Pharma to strike larger and larger deals with the company, says founder and CEO Sean McClain.

https://lnkd.in/eG6_MP6d

Absci
Sean McClain
#Investing #biotech #drugdevelopment #AI 

We are delighted to welcome Prof Sir Mene Pangalos to our Board of Directors and as Co-Chair of our Scientific Advisory Board. Mene brings a wealth of experience from his distinguished career, most recently as EVP of BioPharmaceuticals R&D at AstraZeneca. https://lnkd.in/grVddSSN

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	2.06M -	4.78M 132.04%	4.78M 0.04%	5.75M 20.18%	5.72M 0.50%
cost of revenue					14.00M -
gross profit	2.06M -	4.78M 132.04%	4.78M 0.04%	5.75M 20.18%	-8.28M 244.09%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	3.52M -	5.50M 56.17%	28.78M 423.08%	40.55M 40.90%	37.83M 6.71%
research and development expenses	4.31M -	11.45M 165.55%	44.59M 289.47%	58.91M 32.12%	47.57M 19.25%
other expenses	491K -	1.13M 130.35%	6.65M 488.33%	13.04M 95.93%	6.06M 53.52%
cost and expenses	8.32M -	18.08M 117.19%	80.02M 342.56%	112.50M 40.59%	99.40M 11.64%
operating expenses	8.32M -	18.08M 117.19%	80.02M 342.56%	112.50M 40.59%	85.40M 24.09%
interest expense	268K -	634K 136.57%	3.43M 441.32%	972K 71.68%	1.01M 3.91%
ebitda	-5.83M -	-12.59M 116.10%	-99.77M 692.60%	-91.36M 8.44%	-79.68M 12.78%
operating income	-6.26M -	-13.30M 112.31%	-75.24M 465.66%	-106.75M 41.88%	-93.68M 12.24%
depreciation and amortization	440K -	713K 62.05%	-24.54M 3,541.09%	15.39M 162.74%	14.00M 9.06%
total other income expenses net	-319K -	-1.05M 229.78%	-34.62M 3,190.97%	1.39M 104.00%	-16.79M 1,311.99%
income before tax	-6.58M -	-14.35M 118.00%	-109.86M 665.41%	-105.36M 4.09%	-110.47M 4.84%
income tax expense	217K -	216K 0.46%	-8.90M 4,219.91%	-461K 94.82%	100K 121.69%
net income	-6.80M -	-14.57M 114.22%	-100.96M 592.98%	-104.90M 3.91%	-110.57M 5.40%
weighted average shs out	90.38M -	90.38M 0%	49.69M 45.02%	90.85M 82.84%	92.03M 1.30%
weighted average shs out dil	90.38M -	90.38M 0%	49.69M 45.02%	90.85M 82.84%	92.03M 1.30%
eps	-0.08 -	-0.16 112.48%	-2.03 1,168.75%	-1.15 43.35%	-1.20 4.35%
epsdiluted	-0.08 -	-0.16 112.48%	-2.03 1,168.75%	-1.15 43.35%	-1.20 4.35%

COM:ABSCI

Absci Corporation

Last Close

2.55

22/11 21:00

Market Cap

408.23M

Beta: -

Volume Today

1.09M

Avg: -

Preview